Skip to content
Home/Companies/Biotech/Quince Therapeutics (formerly EryDel)
Quince Therapeutics (formerly EryDel)

Quince Therapeutics (formerly EryDel)

Biotech·United States·Active·7yr hold
Entry
2019
Hold
7yr
Status
Active

Who owns Quince Therapeutics (formerly EryDel)?

Quince Therapeutics (formerly EryDel) is an American Biotech company, currently owned by Sofinnova Partners since 2019.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Capital IX · 2018 · Life Sciences VC

Key facts

HQUnited States
SectorBiotech
Websitequincetx.com

More from Sofinnova Capital IX

Other portfolio companies in the same fund.

Asceneuron
Active
BiotechSwitzerland· 2020
CorVent Medical
CorVent Medical
Active
MedTechUS· 2020
Genespire
Genespire
Active
BiotechItaly· 2020
Nitrase Therapeutics
Nitrase Therapeutics
Active
BiotechUS· 2020
Noema Pharma
Noema Pharma
Exited 2022
BiotechSwitzerland· 2020
to NOEMA PHARMA SA
Pi-Cardia
Pi-Cardia
Active
MedTechIsrael· 2020

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Quince Therapeutics (formerly EryDel)?

Quince Therapeutics (formerly EryDel) is currently owned by Sofinnova Partners, through Sofinnova Capital IX, since 2019.

When did Sofinnova Partners acquire Quince Therapeutics (formerly EryDel)?

Sofinnova Partners acquired Quince Therapeutics (formerly EryDel) in 2019.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue